Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002622 · ClinicalTrials.gov registry record · Phase 3
Talc in Treating Patients With Malignant Pleural Effusion
A Phase 3 study of Metastatic Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 501
- Enrollment target
- 20
- Study locations
NCT00002622: Completed Phase 3 study of Metastatic Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00002622 is a Phase 3 study of Metastatic Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 501 participants, above the 439-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (14% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002622, a Phase 3 study of Metastatic Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 501 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion. PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with malignant pleural effusion.
Conditions Studied
Interventions
- DRUG talc
- DRUG Talc
Study Locations (20)
California
- Providence Saint Joseph Medical Center - Burbank - Burbank
- Mount Diablo Medical Center - Concord
- Beckman Research Institute, City of Hope - Duarte
- California Cancer Center - Fresno
- Saint Agnes Cancer Center - Fresno
- Glendale Memorial Hospital and Health Center - Glendale
- Sutter Health Western Division Cancer Research Group - Greenbrae
- Loma Linda University Medical Center - Loma Linda
- Veterans Affairs Medical Center - Long Beach - Long Beach
- Kaiser Permanente Medical Center - Los Angeles - Los Angeles
Alabama
- Veterans Affairs Medical Center - Birmingham - Birmingham
- University of Alabama Comprehensive Cancer Center - Birmingham
- Huntsville Hospital System - Huntsville
- Urology Associates - Mobile AL - Mobile
- MBCCOP - University of South Alabama - Mobile
- Alabama Oncology, LLC - Montgomery
- Radiation Oncology Associates of West Alabama - Tuscallosa
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
- Arizona Cancer Center - Tucson
Alaska
- Providence Cancer Therapy Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 1994-12 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00002622 record still lists
NCT00002622 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 439-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which talc is the first listed.
NCT00002622 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00002622 about?
NCT00002622 is a clinical study titled "Talc in Treating Patients With Malignant Pleural Effusion". RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion. PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with mal...
What is the current status of trial NCT00002622?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 1994-12. Estimated completion is 2006-01.
What conditions does trial NCT00002622 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT00002622?
The interventions under investigation include: talc (DRUG), Talc (DRUG).
Who is sponsoring clinical trial NCT00002622?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002622 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002622's enrollment target sits among peer trials
501 8th of 109 higher than 102 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
RECRUITING · Phase 3
-
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
COMPLETED · Phase 3
-
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia